MetaCap

Context Therapeutics (CNTX) vs Psyence Biomedical (PBM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Context Therapeutics (CNTX) has outperformed Psyence Biomedical (PBM) over the past year, losing 85.3% versus a loss of 94.9%. Psyence Biomedical is the larger company by market cap ($15.8 million vs $14.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTX-85.32%PBM-94.90%
+223%+56%-111%
Nov 21, 20251 yearNov 20, 2026
CNTX-97.03%PBM-100.00%
+25%-41%-106%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTX versus PBM key metrics
MetricCNTXPBM
Share price$0.16$2.97
Market cap$14.70M$15.80M
1-day change-5.10%+3.85%
YTD return-89.12%-89.90%
1-year return-85.32%-94.90%
5-year return-96.86%—
EPS (TTM)$-0.46$-12.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-36.12M$1.01M
52-week high$3.62$73.44
52-week low$0.153$1.92
Distance from 52-week high-95.58%-95.96%
Analyst consensusnone—
Avg. price target upside+2418.75%—
Average volume1.42M61.93K
Shares outstanding91.88M5.32M
Employees1512
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Context Therapeutics

CNTX stock →

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Psyence Biomedical

PBM stock →

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

CNTX vs PBM FAQ

Which is bigger, Context Therapeutics or Psyence Biomedical?

Psyence Biomedical (PBM) is larger, with a market capitalization of $15.80M compared with $14.70M for Context Therapeutics (CNTX).

Which stock has performed better over the past year, CNTX or PBM?

CNTX returned -85.32% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.

Are Context Therapeutics and Psyence Biomedical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons